Atea says Phase 3 C-BEYOND trial shows hepatitis C combo bemnifosbuvir/ruzasvir matches Epclusa on cure rates
AVIR•Next updates expected
Detailed results are slated for future medical conferences and peer-reviewed publication; a second Phase 3 readout outside North America is expected in early 2027.
Phase 3 trial meets primary and secondary endpoints
Atea Pharmaceuticals reported positive topline results from its Phase 3 C-BEYOND North America trial of bemnifosbuvir/ruzasvir for chronic hepatitis C.
The regimen met the primary and secondary endpoints, matching a standard-of-care therapy in a head-to-head study.
8-week course and safety profile support development
Results support an 8-week course for patients without cirrhosis, positioning the program as a potential shorter-duration option in a large segment.
The study showed a comparable safety profile, with no drug-related serious events or early discontinuations reported.
